Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease

Science Translational Medicine

Volumn 3, Issue 96, 2011, Pages

  Dudley, Joel T ^a,b   Sirota, Marina ^a,b   Shenoy, Mohan ^a   Pai, Reetesh K ^a   Roedder, Silke ^a,b   Chiang, Annie P ^a,b   Morgan, Alex A ^a,b   Sarwal, Minnie M ^a,b   Pasricha, Pankaj Jay ^a   Butte, Atul J ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LUCILE PACKARD CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; PREDNISOLONE; TOPIRAMATE; TRINITROBENZENESULFONIC ACID; ANTICONVULSIVE AGENT; DRUG DERIVATIVE; FRUCTOSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG REPOSITIONING; DRUG SAFETY; ENDOSCOPY; ENTERITIS; GENE EXPRESSION PROFILING; MALE; MATHEMATICAL COMPUTING; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; ULCERATIVE COLITIS; BIOLOGY; GENETICS; HUMAN; METABOLISM; METHODOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTICONVULSANTS; COMPUTATIONAL BIOLOGY; FRUCTOSE; HUMANS; INFLAMMATORY BOWEL DISEASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 80051831092     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3002648     Document Type: Article

References (23)

1. E V Loftus Jr., Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 126, 1504-1517 (2004).
2. D C Baumgart, W J Sandborn, Inflammatory bowel disease: Clinical aspects and established and evolving therapies. Lancet 369, 1641-1657 (2007).
3. B E Sands, F.H. Anderson, C N Bernstein, W Y Chey, B G Feagan, R.N. Fedorak,M A Kamm, J R Korzenik, B A Lashner, J E Onken, D. Rachmilewitz, P. Rutgeerts, G. Wild, D C Wolf, P A Marsters, S B Travers, M A Blank, S J Van Deventer, Infliximab maintenance therapy for fistulizing Crohn's disease. N. Engl. J. Med. 350, 876-885 (2004).
4. M. Sirota, J T Dudley, J. Kim, A P Chiang, A A Morgan, A. Sweet-Cordero, J. Sage, A J Butte, Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci. Transl. Med. 3, 96ra77 (2011).
5. J. Lamb, E D Crawford, D. Peck, J W Modell, I C Blat, M J Wrobel, J. Lerner, J P Brunet, A. Subramanian, K N Ross, M. Reich, H. Hieronymus, G. Wei, S A Armstrong, S J Haggarty, P A Clemons, R. Wei, S A Carr, E S Lander, T R Golub, The Connectivity Map: Using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929-1935 (2006).
6. T. Barrett, T O Suzek, D B Troup, S E Wilhite, W C Ngau, P. Ledoux, D. Rudnev, A E Lash, W. Fujibuchi, R. Edgar, NCBI GEO: Mining millions of expression profiles - Database and tools. Nucleic Acids Res. 33, D562-D566 (2005).
7. P M Irving, R B Gearry, M P Sparrow, P R Gibson, Review article: Appropriate use of corticosteroids in Crohn's disease. Aliment. Pharmacol. Ther. 26, 313-329 (2007).
8. A. Thiry, J M Dogné, C T Supuran, B. Masereel, Anticonvulsant sulfonamides/sulfamates/sulfamides with carbonic anhydrase inhibitory activity: Drug design and mechanism of action. Curr. Pharm. Des. 14, 661-671 (2008).
9. V. Khanna, S. Arumugam, S. Roy, S. Mittra, V S Bansal, Topiramate and type 2 diabetes: An old wine in a new bottle. Expert Opin. Ther. Targets 12, 81-90 (2008).
10. K. Stenlöf, S. Rössner, F. Vercruysse, A. Kumar, M. Fitchet, L. Sjöström; OBDM-003 Study Group, Topiramate in the treatment of obese subjects with drug-naive type 2 diabetes. Diabetes Obes. Metab. 9, 360-368 (2007).
11. R. Bhat, R. Axtell, A. Mitra, M. Miranda, C. Lock, R W Tsien, L. Steinman, Inhibitory role for GABA in autoimmune inflammation. Proc. Natl. Acad. Sci. U.S.A. 107, 2580-2585 (2010).
12. E. Mizoguchi, R J Xavier, H C Reinecker, H. Uchino, A K Bhan, D K Podolsky, A. Mizoguchi, Colonic epithelial functional phenotype varies with type and phase of experimental colitis. Gastroenterology 125, 148-161 (2003).
13. T M Woodruff, T V Arumugam, I A Shiels, R C Reid, D P Fairlie, S M Taylor, A potent human C5a receptor antagonist protects against disease pathology in a rat model of inflammatory bowel disease. J. Immunol. 171, 5514-5520 (2003).
14. E. Rivera, I. Flores, E. Rivera, C B Appleyard, Molecular profiling of a rat model of colitis: Validation of known inflammatory genes and identification of novel disease-associated targets. Inflamm. Bowel Dis. 12, 950-966 (2006).
15. F. Scheiffele, I J Fuss, Induction of TNBS colitis in mice. Curr. Protoc. Immunol. Chapter 15, Unit 15.19 (2002).
16. J C Hoffmann, N N Pawlowski, A A Kühl, W. Höhne, M. Zeitz, Animal models of inflammatory bowel disease: An overview. Pathobiology 70, 121-130 (2002).
17. K N Roy Chengappa, L K Schwarzman, J F Hulihan, J. Xiang, N R Rosenthal; Clinical Affairs Product Support Study-168 Investigators, Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: A randomized, placebo-controlled trial. J. Clin. Psychiatry 67, 1698-1706 (2006).
18. R. Chen, L. Li, A J Butte, AILUN: Reannotating gene expression data automatically. Nat. Methods 4, 879 (2007).
19. V G Tusher, R. Tibshirani, G. Chu, Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. U.S.A. 98, 5116-5121 (2001).
20. A R Jurjus, N N Khoury, J M Reimund, Animal models of inflammatory bowel disease. J. Pharmacol. Toxicol. Methods 50, 81-92 (2004).
21. S. Wirtz, C. Neufert, B. Weigmann, M F Neurath, Chemically induced mouse models of intestinal inflammation. Nat. Protoc. 2, 541-546 (2007).
22. H S Cooper, S N Murthy, R S Shah, D J Sedergran, Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab. Invest. 69, 238-249 (1993).
23. Acknowledgments: We thank A. Skrenchuk and B. Oskotsky (Stanford University) for computer support and E. Davydov, C. Do, S. Gross, and M. Schaub (Stanford University) for constructive discussion. Funding: This work was supported by Lucile Packard Foundation for Children's Health, the Hewlett Packard Foundation, National Institute of General Medical Sciences (R01 GM079719), National Cancer Institute (R01 CA138256), National Library of Medicine (T15 LM007033), Howard Hughes Medical Institute, and Pharmaceutical Research and Manufacturers of America Foundation. Author contributions: J.T.D., M. Sirota, and A.J.B. designed the study and carried out the analysis. M. Shenoy, M.M.S., R.K.P., S.R., and P.J.P. carried out validation experiments. A.A.M. and A.P.C. assisted in the analysis. J.T.D., M. Sirota, and A.J.B. wrote the paper. Competing interests: A.J.B. is on the scientific advisory board of NuMedii Inc. and Personalis and is a paid consultant for Lilly, Johnson and Johnson, Genstruct, Tercica, Ansh Labs, and Prevendia. J.T.D. is a consultant for NuMedii Inc. The other authors declare that they have no competing interests.